menu
    • menu

    Company profile for LaNova Medicines

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    LaNova Medicines is a privately-held China-based global biotech company incorporated in 2019. The company is committed to the discovery, development and, in the future, commercialization of novel biological drugs with “First-in-class” or “Best-in-class” potential in the areas of tumor associated antigens and immuno-oncology in tumor microenvironment to address significant unmet medical needs. Developer of pharmaceuti...
    LaNova Medicines is a privately-held China-based global biotech company incorporated in 2019. The company is committed to the discovery, development and, in the future, commercialization of novel biological drugs with “First-in-class” or “Best-in-class” potential in the areas of tumor associated antigens and immuno-oncology in tumor microenvironment to address significant unmet medical needs. Developer of pharmaceutical technology and biotechnology focusing on tumor immunity and tumor microenvironment therapy.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    LaNova MedicinesChina Flag
    Country
    Country
    China
    Address
    Address
    Floor 4-5, Building 1, Lishui International Technology Innovation Center, No. ...
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://www.lanovamed.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Sino Biopharma to Acquire Lanova Medicines for Up to $951 M
    Sino Biopharma to Acquire Lanova Medicines for Up to $951 M

    16 Jul 2025

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/sino-biopharmaceutical-acquire-lanova-medicines-up-951-million-2025-07-15/

    REUTERS
    16 Jul 2025
    Share Share
    GI Innovation-LaNova Signs MOU for GI-102 + ADC Cancer Therapy
    GI Innovation-LaNova Signs MOU for GI-102 + ADC Cancer Therapy

    22 Jan 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/gi-innovation-lanova-medicines-signs-mou-for-gi-102--adc-pancreatic-cancer-combination-therapy-302356896.html

    PR NEWSWIRE
    22 Jan 2025
    Share Share
    Merck signs up to $3.3 billion cancer drug deal with LaNova
    Merck signs up to $3.3 billion cancer drug deal with LaNova

    16 Nov 2024

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/merck-signs-33-bln-deal-experimental-cancer-drug-2024-11-14/

    REUTERS
    16 Nov 2024
    Share Share
    Merck Licenses LM-299, Anti-PD-1/VEGF Bispecific Antibody
    Merck Licenses LM-299, Anti-PD-1/VEGF Bispecific Antibody

    14 Nov 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241114297701/en

    BUSINESSWIRE
    14 Nov 2024
    Share Share
    LaNova Initiates Phase 1 Trial Of Bispecific Antibody LM-299
    LaNova Initiates Phase 1 Trial Of Bispecific Antibody LM-299

    18 Oct 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/lanova-medicines-announces-initiation-of-phase-1-clinical-trial-of-anti-pd-1vegf-bispecific-antibody-lm-299-and-completion-of-42-million-series-c1-financing-302280157.html

    PR NEWSWIRE
    18 Oct 2024
    Share Share
    AstraZeneca enters potential $600M licensing deal with Chinese startup
    AstraZeneca enters potential $600M licensing deal with Chinese startup

    16 May 2023

    // Katherine Lewin ENDPTS

    https://endpts.com/adding-to-antibody-drug-conjugate-portfolio-astrazeneca-enters-potential-600m-licensing-deal-with-lanova/

    Katherine Lewin ENDPTS
    16 May 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search